Crossmark Global Holdings’s Ascendis Pharma A/S ASND Stock Holding History

Crossmark Global Holdings’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,783	Closed	-$1.78M	–	1264
2026 Q1	$1.78M	Buy	7,783 +390	+5%	+$87.4K	0.03%	460
2025 Q4	$1.58M	Buy	7,393 +2,499	+51%	+$516K	0.02%	490
2025 Q3	$973K	Sell	4,894 -474	-9%	-$88.4K	0.01%	637
2025 Q2	$927K	Sell	5,368 -480	-8%	-$78.2K	0.02%	644
2025 Q1	$911K	Sell	5,848 -4,587	-44%	-$655K	0.02%	644
2024 Q4	$1.44M	Buy	10,435 +2,315	+29%	+$304K	0.03%	479
2024 Q3	$1.21M	Buy	+8,120	New	+$1.1M	0.02%	544

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Crossmark Global Holdings's ASND Position: Q2 2026 in Review

Crossmark Global Holdings sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 7,783 shares — an estimated $1.78M sold.

Crossmark Global Holdings first reported a position in ASND in Q3 2024 and held it in 7 quarters. The position peaked at $1.78M in Q1 2026. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Crossmark Global Holdings reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Crossmark Global Holdings sold 7,783 Ascendis Pharma A/S shares in Q2 2026, an estimated $1.78M.
Crossmark Global Holdings first reported a position in Ascendis Pharma A/S in Q3 2024 and held it in 7 quarters.
Crossmark Global Holdings's Ascendis Pharma A/S position peaked at $1.78M in Q1 2026.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.